> Print and Download Article

Why researchers now believe obesity may require long-term management, and why personalized nutrition coaching may matter more than ever.

For years, most conversations about weight loss focused on one question:

“How do people lose weight?”

But now scientists are asking a different question:

“How do people keep the weight off?”

That may be one of the most important questions in obesity medicine today.

Two major studies are helping researchers better understand what happens after weight loss with GLP-1 medications like:

• Zepbound
• Mounjaro
• Wegovy
• Ozempic

These were not simple company presentations or marketing claims.

The studies were:

• randomized,
• placebo-controlled,
• peer-reviewed,
• phase 3 clinical trials,
• and double-blind during the maintenance phase.

This type of study design is considered:

the gold standard in medical research.

That means researchers carefully designed the studies to reduce bias and better understand what was truly happening biologically.

The studies focused on something millions of people worry about:

Weight regain.

The Two Major Studies

The two studies were:

1. SURMOUNT-MAINTAIN
2. ATTAIN-MAINTAIN

These studies were presented at the European Congress on Obesity and published in two respected medical journals:

• The Lancet
• Nature Medicine

Researchers wanted to answer several important questions:

• What happens after major weight loss?
• Can people lower their dose and still maintain results?
• Can people stop the medication completely?
• Could oral GLP-1 medications eventually replace injections for maintenance?

What Was the SURMOUNT-MAINTAIN Study?

The SURMOUNT-MAINTAIN study followed adults with obesity for:

112 weeks, a little more than 2 years.

Participants first took tirzepatide for about 60 weeks.

Most participants used:

• 10 mg
• or 15 mg doses.

Researchers noted that many participants had already reached a:

weight-loss plateau

before the maintenance phase began.

That means most participants had already achieved most of the weight loss expected from the medication before researchers tested maintenance strategies.

After that, participants were divided into 3 groups.

Group 1

Stayed on the full dose

Group 2

Reduced to 5 mg

Group 3

Stopped the medication and received a placebo injection instead.

A placebo is an injection that does not contain the real medication.

The Lifestyle Intervention Is Very Important

One of the biggest details in these studies is something many people may overlook.

Every participant continued lifestyle intervention.

Participants still received:

• nutrition counseling,
• physical activity guidance,
• behavioral support,
• accountability,
• and ongoing coaching.

Even the placebo group continued:

• healthier eating plans,
• exercise guidance,
• and counseling support.

This is important because many people believe:

“If someone simply builds better habits, they should be able to maintain the weight without medication.”

These studies strongly challenge that assumption.

What Did Researchers Discover?

Staying on the Full Dose Worked Best

People who stayed on the full dose maintained almost all of their weight loss.

After 112 weeks:

their average weight remained about 21.9% lower than when they started.

Researchers found that these participants remained very stable during the maintenance phase.

Lower Doses Still Helped

People who lowered their dose to 5 mg still maintained meaningful weight loss.

Their average weight remained:

16.6% below baseline.

However:

they regained about 13 pounds on average.

Even so, the lower dose still worked much better than stopping completely.

Stopping the Medication Led to Significant Weight Regain

This was one of the most important findings.

Participants who stopped the medication regained much more weight.

On average:

they regained about 28 pounds.

Researchers also found:

about 67% of people who stopped treatment eventually needed rescue medication because they regained too much weight.

This happened even though participants still continued:

• healthier eating,
• exercise,
• and lifestyle support.

What Does This Tell Us?

The studies suggest something very important:

Obesity is strongly connected to biology.

Researchers explained that after weight loss, the body often tries to regain lost fat.

Scientists sometimes describe this as the body trying to:

“defend” its previous body weight.

This may involve:

• hunger hormones,
• appetite signals,
• metabolism,
• brain signaling,
• and energy regulation.

This helps explain why so many people struggle with long-term weight maintenance after dieting.

 

 The Studies Challenge the “Willpower” Argument

For years, many people were told:

“Just eat less and move more.”

But these studies suggest the story is much more complicated.

Even with:

• nutrition counseling,
• exercise,
• and accountability,

many participants still regained substantial weight after stopping treatment.

That does NOT mean nutrition and exercise do not matter.

They absolutely matter.

But the studies suggest obesity is more than simply:

calories in versus calories out.

Researchers increasingly describe obesity as: a chronic disease.

An Important Perspective About Lifestyle Intervention

One important thing to understand is that not all lifestyle interventions are the same.

In these studies, participants received:

• nutrition counseling,
• exercise guidance,
• and behavioral support.

However, the published studies did not fully explain:

• how personalized the coaching was,
• how nutrition education was delivered,
• whether the counseling addressed emotional eating,
• cultural food preferences,
• affordability,
• metabolic differences,
• or whether participants received individualized coaching designed to truly meet people where they are.

That distinction matters.

General lifestyle counseling often focuses on:

• calorie reduction,
• generic nutrition advice,
• and exercise recommendations.

But many experts believe long-term success may improve when nutrition education becomes more personalized and sustainable.

For example, the Diet Free Life methodology focuses on:

• meeting people where they are,
• customizing meals around culture and affordability,
• improving metabolic flexibility,
• stabilizing blood sugar and insulin response,
• and helping people build sustainable eating patterns without food deprivation.

It is possible that more personalized coaching approaches could improve long-term maintenance outcomes compared to generalized lifestyle intervention alone.

However, more research is still needed to better understand:

• which behavioral strategies work best,
• which nutrition approaches improve long-term maintenance,
• and how personalized coaching may affect weight regain after GLP-1 treatment.

Rescue Therapy Is Important

The studies also included something called: rescue therapy.

If participants regained too much weight, they were allowed to restart tirzepatide treatment.

Researchers did this because they recognized that significant regain could negatively affect health.

That is an important detail because it shows:

• researchers expected regain to occur,
• and they considered it serious enough to intervene.

Blood Sugar and Health Markers Also Improved

The studies showed that participants staying on treatment maintained better:

• blood sugar,
• blood pressure,
• triglycerides,
• waist size,
• and metabolic health.

Among participants who started with pre-diabetes:

• about 93% of those staying on the full dose maintained healthy HbA1c levels,
• compared to only about 51% in the placebo group.

That is a very large difference.

Researchers also found that many cardio-metabolic improvements began worsening after participants stopped treatment.

This included:

• blood sugar control,
• blood pressure,
• triglycerides,
• and waist circumference.

That means the conversation is not only about body weight.

It is also about: long-term metabolic health.

Another Study Looked at Pills Instead of Injections

The ATTAIN-MAINTAIN study explored another important question:

“Could people switch from injections to a pill and still maintain weight loss?”

Participants switched to an oral GLP-1 medication called: orforglipron.

Researchers found that many participants still maintained much of their weight loss while taking the pill.

This suggests oral GLP-1 medications may eventually become another long-term maintenance option.

What About Intermediate Doses?

One interesting point is that the studies mainly tested:

• 5 mg,
• 10 mg,
• and 15 mg doses.

The studies did NOT formally test:

• 7.5 mg
• or 12.5 mg
  as long-term maintenance strategies.

That does not mean those doses do not work.

It simply means: they were not formally studied in these trials.

This is important because many patients may still respond well to intermediate doses depending on:

• tolerability,
• side effects,
• insurance coverage,
• affordability,
• and individual biology.

One Important Question Scientists Still Do Not Know

One important fact many people do not realize is this:

Natural GLP-1 released after eating lasts only about 1–2 minutes.

But GLP-1 medications stimulate these pathways continuously for days at a time.

Scientists still do not fully know:

• what happens after 5 or 10 years,
• how the body adapts to long-term stimulation,
• or the long-term effects on muscle mass and metabolism.

The studies also did not fully answer questions about:

• muscle preservation,
• food noise,
• body composition,
• emotional eating,
• or long-term psychological adaptation.

That is one reason more long-term research is still needed.

A Simple Analogy

Imagine your appetite system is like a thermostat.

Natural GLP-1 briefly lowers hunger after eating.

But GLP-1 medications keep the thermostat turned down for much longer.

Researchers are still studying what happens when that system is continuously stimulated for years.

What Is the Biggest Message From These Studies?

The biggest message may be this: GLP-1 medications appear to work best while people continue taking them.

The studies showed:

• staying on treatment worked best,
• lowering the dose still helped,
• and stopping treatment led to the most regain.

Researchers increasingly view obesity more like:

• high blood pressure,
• diabetes,
• or high cholesterol.

In other words:

Obesity may require long-term management.

Looking for Personalized Support?

If you are:

• currently taking a GLP-1 medication,
• thinking about starting one,
• struggling with weight regain,
• or looking for a long-term strategy to improve your health,

the Diet Free Life methodology may help.

Our programs focus on:

• personalized nutrition coaching,
• metabolic flexibility,
• blood sugar stabilization,
• sustainable meal planning,
• and helping people build healthier habits without food deprivation.

We also offer programs designed specifically for:

• people currently using GLP-1 medications,
• and people looking to transition off GLP-1 drugs while improving long-term metabolic health.

You can schedule a free consultation or learn more about our meal plans here: https://dietfreelife.store/meal-plans/

Final Thoughts

These studies are helping researchers better understand:

• obesity,
• appetite,
• metabolism,
• weight regain,
• and long-term weight management.

They also help explain why many people regain weight after dieting.

Most importantly, these studies suggest: many people struggling with weight regain were not simply lacking discipline, their biology was pushing back.

At the same time, long-term health is still about more than body weight alone.

Nutrition quality, muscle health, inflammation, insulin sensitivity, metabolic flexibility, and overall metabolic health still matter greatly.

Weight loss is only one piece of the health puzzle.

References

1. 1. Aron, L. J., et al. (2026). Maintenance of weight loss after transition from injectable GLP-1 therapy to oral orforglipron in adults with obesity: The ATTAIN-MAINTAIN trial. Nature Medicine.
   2. Horn, D. B., et al. (2026). Tirzepatide maintenance therapy in adults with obesity: Results from the SURMOUNT-MAINTAIN trial. The Lancet.
   3. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216.
   4. Rubino, D., et al. (2023). Effect of continued weekly subcutaneous tirzepatide vs placebo on weight maintenance in adults with obesity or overweight. JAMA, 330(6), 512–523.
   5. Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002.
   6. ClinicalTrials.gov. (2026). SURMOUNT-MAINTAIN Trial (NCT06047548). Retrieved from ClinicalTrials.gov SURMOUNT-MAINTAIN Trial
   7. ClinicalTrials.gov. (2026). SURMOUNT-4 Trial (NCT04660643). Retrieved from

__________
Robert Ferguson is a California- and Florida-based single father of two daughters, clinical nutritionist, Omega Balancing Coach™, researcher, best-selling author, speaker, podcast and television host, health advisor, NAACP Image Award Nominee, creator of the Diet Free Life methodology, and Chief Nutrition Officer for iCoura Health. He also serves on the Presidential Task Force on Obesity for the National Medical Association and the Health and Product Advisory Board for Zinzino, Inc.

🗓️ Schedule a FREE consultation with Robert Ferguson about becoming a client: SCHEDULE FREE CONSULTATION

👉🏽 To order the BalanceOil+ with the BalanceTEST, > CLICK HERE

👉🏽 Watch a free online presentation on the BalanceOil+ and the BalanceTEST: WATCH NOW.